3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Transitional Cell
37
Urinary Bladder Neoplasms
33
Carcinoma, Renal Cell
30
Carcinoma, Non-Small-Cell Lung
16
Melanoma
15
Prostatic Neoplasms
13
Stomach Neoplasms
10
Carcinoma, Hepatocellular
10
Triple Negative Breast Neoplasms
9
Kidney Neoplasms
9
Colorectal Neoplasms
9
Head and Neck Neoplasms
8
Uterine Cervical Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
7
Small Cell Lung Carcinoma
7
Neoplasms
7
Neoplasm Metastasis
6
Lung Neoplasms
6
Breast Neoplasms
6
Ovarian Neoplasms
5
Carcinoma, Merkel Cell
5
Urologic Neoplasms
4
Pancreatic Neoplasms
4
Urethral Neoplasms
3
Ureteral Neoplasms
3
Esophageal Neoplasms
3
Carcinoma, Squamous Cell
3
Sarcoma
2
Prostatic Neoplasms, Castration-Resistant
2
Neuroendocrine Tumors
2
Interventions
Magnetic Resonance Spectroscopy
5
Radiosurgery
4
luprolide acetate gel depot
3
enzalutamide
3
Radiotherapy
3
Radiation
3
Leuprolide
3
Goserelin
3
relugolix
2
gallium 68 PSMA-11
2
bicalutamide
2
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
2
Triptorelin Pamoate
2
Specimen Handling
2
Proton Therapy
2
Biopsy
2
radium Ra 223 dichloride
1
niraparib
1
histrelin
1
fluciclovine F-18
1
flibanserin
1
entinostat
1
darolutamide
1
atezolizumab
1
apalutamide
1
abiraterone
1
X-Rays
1
Watchful Waiting
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostate Adenocarcinoma
×
atezolizumab
×
Genitourinary
×
Clear all
NCT04020094
2021-09-22
AtezoVax
University of Utah
Phase 2
Withdrawn